A spin-out from UC Berkeley, GenEdit develops tissue-selective polymeric nanoparticles for extra-hepatic delivery of genetic cargoes. Internal clinical leads target CNS disorders, while partnerships inked with Sarepta and Genentech and other recognized pharma players.
A stealth-mode spin-out from UC Berkeley, Axent develops stem cell therapies via breakthrough innovations in 3D cell expansion, differentiation, and delivery.
A stealth-mode startup from University of Maryland developing an ASIT therapy delivery platform for autoimmune diseases.
A stealth-mode spin-out from Jacob Hanna's lab at the Weizmann Institute, Renewal Bio is advancing a therapeutic platform technology to build synthetic embryos for transplantation in fertility and longevity.
Stealth-mode company developing an in vivo gene editing platform using antibody-targeted, thermostable RNA–LNPs.
Pasqal is a pioneer in quantum computing, delivering quantum advantage in drug design and a variety of real-world computational tasks.
An IndieBio alum, Proteinea develops proprietary AI models for protein engineering that are applicable to multi-parameter optimization of complex proteins.
A spin-out from UC Berkeley, GenEdit develops tissue-selective polymeric nanoparticles for extra-hepatic delivery of genetic cargoes. Internal clinical leads target CNS disorders, while partnerships inked with Sarepta and Genentech and other recognized pharma players.
A stealth-mode spin-out from UC Berkeley, Axent develops stem cell therapies via breakthrough innovations in 3D cell expansion, differentiation, and delivery.
A stealth-mode startup from University of Maryland developing an ASIT therapy delivery platform for autoimmune diseases.
A stealth-mode spin-out from Jacob Hanna's lab at the Weizmann Institute, Renewal Bio is advancing a therapeutic platform technology to build synthetic embryos for transplantation in fertility and longevity.
Stealth-mode company developing an in vivo gene editing platform using antibody-targeted, thermostable RNA–LNPs.
Pasqal is a pioneer in quantum computing, delivering quantum advantage in drug design and a variety of real-world computational tasks.
An IndieBio alum, Proteinea develops proprietary AI models for protein engineering that are applicable to multi-parameter optimization of complex proteins.
A spin-out from UC Berkeley, GenEdit develops tissue-selective polymeric nanoparticles for extra-hepatic delivery of genetic cargoes. Internal clinical leads target CNS disorders, while partnerships inked with Sarepta and Genentech and other recognized pharma players.
A stealth-mode spin-out from UC Berkeley, Axent develops stem cell therapies via breakthrough innovations in 3D cell expansion, differentiation, and delivery.
A stealth-mode startup from University of Maryland developing an ASIT therapy delivery platform for autoimmune diseases.
A stealth-mode spin-out from Jacob Hanna's lab at the Weizmann Institute, Renewal Bio is advancing a therapeutic platform technology to build synthetic embryos for transplantation in fertility and longevity.
Stealth-mode company developing an in vivo gene editing platform using antibody-targeted, thermostable RNA–LNPs.
Pasqal is a pioneer in quantum computing, delivering quantum advantage in drug design and a variety of real-world computational tasks.
An IndieBio alum, Proteinea develops proprietary AI models for protein engineering that are applicable to multi-parameter optimization of complex proteins.
We benefit from AI-powered tracking of a 30M+ scientific article database.
We run weekly journal clubs on scientific articles in our focus.
We make 10 warm VC intros for every new portfolio company.
We are backed by large institutions with an appetite for direct investments.
We assist our portfolio in hiring c-level employees and advisors.
